維亞生物(01873.HK):3.92億元成功競投浦東新區工廈物業
格隆匯7月1日丨維亞生物(01873.HK)宣佈,於2020年7月1日,公司間接全資附屬維亞生物科技(上海)透過上海市浦東新區人民法院在淘寶網發佈的網絡拍賣方式以競投價人民幣約3.92億元成功競投該物業的土地使用權,並於同日獲得網絡拍賣確認書。
據悉,該物業(房地產權證號為浦2013225506)位於上海市浦東新區周浦鎮紫萍路735號。該物業包括三棟物業,建築面積約為40,018平方米。該物業的使用期限於2063年5月23日屆滿,並指定作工業用途。
公司表示,預期收購該物業將提供經營空間以滿足集團於未來數年的業務增長及發展。隨着上海土地日益緊缺,上海主要地區的租賃設施成本將持續增加,收購該物業將減少集團未來的租賃成本,為集團的業務帶來協同效應,並提升其企業形象。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.